The incidence of alopecia areata significantly increased after COVID-19, a nationwide study involving more than half a million South Koreans found. In a propensity score-matched analysis, incidence of ...

Please provide your email address to receive an email when new articles are posted on . Rezpegaldesleukin is an interleukin-2 receptor pathway agonist that may stimulate regulatory T-cell expansion ...

Alopecia areata affects 8.3 million people globally, significantly impacting quality of life. PROMs are essential for integrating patient perspectives into drug development and evaluating treatment ...

ARQ-255 is a topical Janus kinase 1 (JAK1) inhibitor suspension formulated as a potential topical treatment for alopecia areata Proprietary Deep Dermal Drug Delivery (4D) technology formulated to ...

A study in San Bernardino County found no increased risks of alopecia areata (AA) after the COVID-19 vaccination but suggests further research into potential geographic and gender-based factors. There ...

The study published in the Journal of Dermatological Treatment by Daniel Muñoz-Barba and colleagues provides valuable ...

Samson Clinical Operations Pty Ltd (Samson) announced completion of the Last Patient Last Visit in its pivotal Phase III clinical trial evaluating low dose sublingual minoxidil in male Androgenetic ...

Please provide your email address to receive an email when new articles are posted on . The first patient has been enrolled in a phase 1b study evaluating ARQ-255 topical suspension 3% in the ...

The stigma of having alopecia causes more depression and anxiety than the disease itself, new research has found. The study, led by King’s College London is the largest of its kind and published in ...